Rapid response to a college outbreak of meningococcal serogroup B disease: Nation's first widespread use of bivalent rLP2086 vaccine |
| |
| Authors: | Theresa M Fiorito Suzanne Bornschein Alysia Mihalakos Catherine M Kelleher Nicole Alexander-Scott Koren V Kanadanian |
| |
| Institution: | 1. Department of Pediatric Infectious Diseases, Hasbro Children's Hospital, The Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA;2. Student Health Center, Providence College, Providence, Rhode Island, USA;3. Rhode Island Department of Health, Center for Emergency Preparedness and Response, Providence, Rhode Island, USA;4. Rhode Island Department of Health, The Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA;5. Emergency Management, Providence College, Providence, Rhode Island, USA |
| |
| Abstract: | Objective: To outline the reasoning behind use of bivalent rLP2086 in a Rhode Island college meningococcal B disease outbreak, highlighting the timeline from outbreak declaration to vaccination clinic, emphasizing that these two time points are <3 days apart. Participants: Staff, faculty, and students at College X eligible for vaccination. Methods: An outbreak response was initiated, advantages/disadvantages of available MenB vaccines were discussed, and a vaccination clinic was coordinated. Results: Bivalent rLP2086 was chosen as the vaccination intervention. We achieved a 94% coverage rate for the first dose. To date, this intervention has prevented further cases of Neisseria meningitidis serogroup B disease at College X. Conclusions: The close, efficient collaboration of public health stakeholders and College X led 94% of the eligible population to be safely vaccinated with at least one dose of bivalent rLP2086. This outbreak marked the first time bivalent rLP2086 was effectively used as an intervention response. |
| |
| Keywords: | Bivalent rLP2086 meningococcal B disease Neisseria meningitidis vaccination |
|
|
